MedPath

PRASCO, LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

1

Active:0
Completed:1

Trial Phases

1 Phases

Phase 3:1

Drug Approvals

54

FDA:54

Drug Approvals

SUMATRIPTAN

Approval Date
Mar 28, 2024
FDA

Metronidazole Topical Gel

Approval Date
Mar 1, 2024
FDA

Dactinomycin

Approval Date
Jan 18, 2024
FDA

DOXYCYCLINE

Approval Date
Jan 17, 2024
FDA

metronidazole

Approval Date
Jan 17, 2024
FDA

Ibuprofen Lysine

Approval Date
Jan 5, 2024
FDA

Lanthanum carbonate

Approval Date
Dec 26, 2023
FDA

Teriparatide

Approval Date
Dec 11, 2023
FDA

Betamethasone Dipropionate

Approval Date
Nov 10, 2023
FDA

Amlodipine and Atorvastatin

Approval Date
Oct 31, 2023
FDA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 3
1 (100.0%)

Study to Evaluate the Equivalence of Estradiol Vaginal Cream to Reference Standard in the Treatment of Vaginal Atrophy

Phase 3
Completed
Conditions
Vulvar and Vaginal Atrophy
Interventions
First Posted Date
2017-11-06
Last Posted Date
2024-05-30
Lead Sponsor
Prasco LLC
Target Recruit Count
540
Registration Number
NCT03332303
Locations
🇺🇸

Douglas Young, MD, Sacramento, California, United States

🇺🇸

Medical Center for Clinical Research, San Diego, California, United States

🇺🇸

Women's Health Care Research Corp., San Diego, California, United States

and more 23 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.